AIM ImmunoTech Announces Launch of CEO Corner Platform
08 March 2024 - 12:45AM
UK Regulatory
AIM ImmunoTech Announces Launch of CEO Corner Platform
CEO Corner segments to provide added
perspective to press releases, corporate developments and pipeline
progress
Provides interested parties the ability to
ask questions and submit topics for future videos
Access the AIM CEO Corner
Here!
OCALA, Fla., March 07, 2024 (GLOBE NEWSWIRE) -- AIM
ImmunoTech Inc. (NYSE American:
AIM) (“AIM” or the “Company”), today announced the
launch of its CEO Corner featuring Thomas K Equels, M.S., J.D.,
Executive Vice Chairman, Chief Executive Officer & President of
AIM ImmunoTech. The CEO Corner platform is intended to provide
additional and in-depth perspective to press releases, corporate
developments and development pipeline progress.
“Keeping our stakeholders well informed is absolutely essential
to the future success of AIM ImmunoTech,” states Equels. “CEO
Corner is a new way for us to connect directly with both current
and potential stockholders. CEO Corner segments will provide
expanded perspective on press releases, clinical trials and other
corporate advancements as we continue to push forward with our
development pipeline. We believe in the future of Ampligen and are
dedicated to growing value for all stakeholders.”
The CEO Corner is now accessible on the Company’s website
here.
About AIM ImmunoTech Inc.
AIM ImmunoTech Inc. is an immuno-pharma company focused on the
research and development of therapeutics to treat multiple types of
cancers, immune disorders and viral diseases, including COVID-19.
The Company’s lead product is a first-in-class investigational drug
called Ampligen® (rintatolimod), a dsRNA and highly
selective TLR3 agonist immuno-modulator with broad spectrum
activity in clinical trials for globally important cancers, viral
diseases and disorders of the immune system.
For more information, please visit aimimmuno.com and
connect with the Company on Twitter, LinkedIn,
and Facebook.
A photo accompanying this announcement is available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/bf36df6a-66a3-4b6b-9b53-57c074b48a66
Aim Immunotech (LSE:0A4Y)
Historical Stock Chart
From Dec 2024 to Jan 2025
Aim Immunotech (LSE:0A4Y)
Historical Stock Chart
From Jan 2024 to Jan 2025